Speaker Profile
Ph.D., Sr. Director, Product Development, Invivoscribe
Biography
Dr. Ying Huang has over 25 years of research and industry experience with a broad knowledge in technology and assay development. Ying is passionate about developing novel methods using innovative technologies to improve lives with precision diagnostics. Her current work is focused on assays for diagnosis, stratification and risk-directed treatment strategies in hematologic disease. Prior to Invivoscribe, she worked at Illumina, Acea Biosciences, Nanogen and MD Anderson Cancer Center. In those roles, she developed a variety of methods ranging from isolating CTC using microfluidic devices, to detecting biowarfare agents using electronic microarray. She is co-author of more than 60 publications and abstracts and is co-inventor on 9 patents. Ying received her Ph.D in Electrical Engineering from Bangor University, UK.
Clinical Dx Showcase:
Invivoscribe
Invivoscribe is a global leader in hemato-oncology diagnostics. Our flow & molecular assays, reagents, controls, bioinformatics & services focus on actionable biomarkers supporting therapeutic decisions, MRD testing, stratification & CDx development.
A Comprehensive Solution for AML Precision Diagnostics
AML is an aggressive, highly heterogeneous disease. Invivoscribe offers a comprehensive solution for AML precision diagnostics, risk stratification, prognosis and treatment strategies using complementary molecular and flow assays to optimize patient care and accelerate drug approvals worldwide.
Session Abstract – PMWC 2022 Silicon Valley
The PMWC 2022 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Nerodegenerative
